S2k guideline for the treatment of hidradenitis suppurativa / acne inversa - Short version.
acne inversa
classification
guideline
hidradenitis suppurativa
severity
therapy
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
21 May 2024
21 May 2024
Historique:
received:
03
12
2023
accepted:
27
02
2024
medline:
21
5
2024
pubmed:
21
5
2024
entrez:
21
5
2024
Statut:
aheadofprint
Résumé
The S2k guideline on hidradenitis suppurativa/acne inversa (HS/AI) aims to provide an accepted decision aid for the selection/implementation of appropriate/sufficient therapy. HS/AI is a chronic recurrent, inflammatory, potentially mutilating skin disease of the terminal hair follicle-glandular apparatus, with painful, inflammatory lesions in the apocrine gland-rich regions of the body. Its point prevalence in Germany is 0.3%, it is diagnosed with a delay of 10.0 ± 9.6 years. Abnormal differentiation of the keratinocytes of the hair follicle-gland apparatus and accompanying inflammation form the central pathogenetic basis. Primary HS/AI lesions are inflammatory nodules, abscesses and draining tunnels. Recurrences in the last 6 months with at least 2 lesions at the predilection sites point to HS/AI with a 97% accuracy. HS/AI patients suffer from a significant reduction in quality of life. For correct treatment decisions, classification and activity assessment should be done with a validated tool, such as the International Hidradenitis Suppurativa Severity Scoring System (IHS4). HS/AI is classified into two forms according to the degree of detectable inflammation: active, inflammatory (mild, moderate, and severe according to IHS4) and predominantly inactive, non-inflammatory (Hurley grade I, II and III) HS/AI. Oral tetracyclines or 5-day intravenous therapy with clindamycin are equal to the effectiveness of clindamycin/rifampicin. Subcutaneously administered adalimumab, secukinumab and bimekizumab are approved for the therapy of HS/AI. Various surgical procedures are available for the predominantly non-inflammatory disease form. Drug/surgical combinations are considered a holistic therapy method.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Deutsche Dermatologische Gesellschaft (DDG).
Références
Zouboulis CC, Bechara FG, Fritz K, et al. S1–Leitlinie zur Therapie der Hidradenitis suppurativa /Acne inversa (ICD‐10 Ziffer: L73.2). J Dtsch Dermatol Ges. 2012;10(Suppl 5):S1‐31.
Zouboulis C, Bechara F, Fritz K, et al. S2k‐Leitlinie zur Therapie der Hidradenitis suppurativa /Acne inversa (ICD‐10‐Code: L73.2). Akt Dermatol. 2024;50:30‐83.
Kirsten N, Frings V, Nikolakis GD, et al. Epidemiologie, Patientenlebensqualität und Behandlungskosten der Hidradenitis suppurativa/Acne inversa. Hautarzt. 2021;72:651‐657.
Jfri A, Nassim D, O'Brien E, et al. Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta‐regression Analysis. JAMA Dermatol. 2021;157:924‐931.
Kirsten N, Zander N, Augustin M. Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population. Arch Dermatol Res. 2021;313:95‐99.
Dajnoki Z, Somogyi O, Medgyesi B, et al. Primary alterations during the development of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2022;36:462‐471.
Zouboulis CC, Nogueira da Costa A, Makrantonaki E, et al. Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2020;34:846‐861.
Zouboulis VA, Zouboulis KC, Zouboulis CC. Hidradenitis suppurativa and comorbid disorder biomarkers, druggable genes, new drugs and drug repurposing – a molecular meta‐analysis. Pharmaceutics. 2021;14:44.
Zouboulis CC, Del Marmol V, Mrowietz U, et al. Hidradenitis suppurativa/acne inversa: Criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015;231:184‐190.
Kokolakis G, Wolk K, Schneider‐Burrus S, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology. 2020;236:421‐430.
Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177:1401‐1409.
Tzellos T, van Straalen KR, Kyrgidis A, et al. Development and validation of IHS4‐55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2023;37:395‐401.
Horváth B, Janse IC, Blok JL, et al. Hurley staging refined: A proposal by the Dutch Hidradenitis Suppurativa Expert Group. Acta Derm Venereol. 2017;97:412‐413.
Zouboulis CC, Bechara FG, Dickinson‐Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization ‐ systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33:19‐31.
van Straalen KR, Tzellos T, Guillem P, et al. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study. J Am Acad Dermatol. 2021;85:369‐378.
Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157:846‐855.
Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate‐to‐severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo‐controlled, double‐blind phase 3 trials. Lancet. 2023;401:747‐761.
Bechara FG, Podda M, Prens EP, et al. Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: The SHARPS randomized clinical trial. JAMA Surg. 2021;156:1001‐1009.
Kurzen H, Kurokawa I, Jemec GBE, et al. What causes hidradenitis suppurativa? Exp Dermatol. 2008;17:455‐456; discussion 457‐472.
Zouboulis CC, Benhadou F, Byrd AS, et al. What causes hidradenitis suppurativa? –15 years after. Exp Dermatol. 2020;29:1154‐1170.
Kirsten N, Petersen J, Hagenström K, Augustin M. Epidemiology of hidradenitis suppurativa in Germany – an observational cohort study based on a multisource approach. J Eur Acad Dermatol Venereol. 2020;34:174‐179.
Jemec GBE, Kimball AB. Hidradenitis suppurativa: Epidemiology and scope of the problem. J Am Acad Dermatol. 2015;73(5 Suppl 1):S4‐7.
Ingram JR. The epidemiology of hidradenitis suppurativa. Br J Dermatol. 2020;183:990‐998.
Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35 2 Pt 1:191‐194.
Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68:412‐419.
Revuz JE, Canoui‐Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case‐control studies. J Am Acad Dermatol. 2008;59:596‐601.
Botvid SHC, Storgaard Hove L, Bouazzi D, et al. Hidradenitis suppurativa prevalence in Nuuk, Greenland: Physician validation of a hidradenitis suppurativa questionnaire in a Greenlandic setting. Acta Derm Venereol. 2023;103:adv00847.
Wolkenstein P, Loundou A, Barrau K, et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56:621‐623.
Kurzen H, Schönfelder‐Funcke S, Hartschuh W. Surgical treatment of acne inversa at the University of Heidelberg. Coloproctology. 2000;22:76‐80.
Nikolakis G, Karagiannidis I, Vaiopoulos AG, et al. Endokrine Mechanismen bei der Pathophysiologie der Hidradenitis suppurativa. Hautarzt. 2020;71:762‐771.
Schneider‐Burrus S, Lux G, van der Linde K, et al. Hidradenitis suppurativa – prevalence analyses of German statutory health insurance data. J Eur Acad Dermatol Venereol. 2021;35:e32‐5.
Schneider‐Burrus S, Tsaousi A, Barbus S, et al. Features associated with quality of life impairment in hidradenitis suppurativa patients. Front Med (Lausanne). 2021;8:676241.
Vazquez BG, Alikhan A, Weaver AL, et al. Incidence of hidradenitis suppurativa and associated factors: a population‐based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133:97‐103.
Vaiopoulos AG, Nikolakis G, Zouboulis CC. Hidradenitis suppurativa in paediatric patients: a retrospective monocentric study in Germany and review of the literature. J Eur Acad Dermatol Venereol. 2020;34:2140‐2146.
Di Cesare A, Nikolakis G, Kanni T, et al. Identification of clinical features affecting diagnostic delay in paediatric hidradenitis suppurativa: results from a multicentre observational study. Br J Dermatol. 2022;187:428‐430.
Loget J, Saint‐Martin C, Guillem P, et al. Errance médicale des patients atteints d'hidradénite suppurée: un problème majeur et persistant. Étude "R‐ENS Verneuil". Ann Dermatol Venereol. 2018;145:331‐338.
Zouboulis CC, Goyal M, Byrd AS. Hidradenitis suppurativa in skin of colour. Exp Dermatol. 2021;30(Suppl 1):27‐30.
Zouboulis CC. The socioeconomic burden of hidradenitis suppurativa/acne inversa. Br J Dermatol. 2019;181:7‐8.
Zouboulis C, Brunner M, Lippert U, et al. Hidradenitis suppurativa /Acne inversa: Aktuelles zur Definition, Epidemiologie, Pathogenese, Klassifikation und Evidenz‐basierten Therapie. Akt Dermatol. 2015;45:185‐199.
Frew JW, Lowes MA, Goldfarb N, et al. Global harmonization of morphological definitions in hidradenitis suppurativa for a proposed glossary. JAMA Dermatol. 2021;157:449‐455.
Canoui‐Poitrine F, Revuz JE, Wolkenstein P, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol. 2009;61:51‐57.
Poli F, Wolkenstein P, Revuz J. Back and face involvement in hidradenitis suppurativa. Dermatology. 2010;221:137‐141.
Benhadou F, Van der Zee HH, Pascual JC, et al. Pilonidal sinus disease: an intergluteal localization of hidradenitis suppurativa/acne inversa: a cross‐sectional study among 2465 patients. Br J Dermatol. 2019;181:1198‐1206.
von Laffert M, Stadie V, Ulrich J, et al. Morphology of pilonidal sinus disease: some evidence of its being a unilocalized type of hidradenitis suppurativa. Dermatology. 2011;223:349‐355.
Breuninger H. Therapie des Pilonidalsinus und der Acne inversa. Hautarzt. 2004;55:254‐258.
Sabat R, Tsaousi A, Ghoreschi K, et al. Sex‐disaggregated population analysis in patients with hidradenitis suppurativa. Front Med (Lausanne). 2022;9:1028943.
Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619‐644.
Nazzaro G, Passoni E, Veraldi S, Marzano AV. Lymph node involvement in hidradenitis suppurativa: Ultrasound and color Doppler study of 85 patients. Skin Res Technol. 2020;26:960‐962.
Wortsman X, Revuz J, Jemec GBE. Lymph nodes in hidradenitis suppurativa. Dermatology. 2009;219:22‐24.
Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60:539‐561;quiz:562‐563.
Menter A. Recognizing and managing comorbidities and complications in hidradenitis suppurativa. Semin Cutan Med Surg. 2014;33(3 Suppl):S54‐56.
Yuan JT, Naik HB. Complications of hidradenitis suppurativa. Semin Cutan Med Surg. 2017;36:79‐85.
Micieli R, Alavi A. Lymphedema in patients with hidradenitis suppurativa: a systematic review of published literature. Int J Dermatol. 2018;57:1471‐1480.
Grada AA, Phillips TJ. Lymphedema: Pathophysiology and clinical manifestations. J Am Acad Dermatol. 2017;77:1009‐1020.
Sachdeva M, Mufti A, Zaaroura H, et al. Squamous cell carcinoma arising within hidradenitis suppurativa: a literature review. Int J Dermatol. 2021;60:e459‐465.
Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010;2:9‐16.
Blum FR, Miles JA, Farag SW, et al. Characterizing the immune checkpoint marker profiles of cutaneous squamous cell carcinomas in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2023;37:e316‐318.
Pena ZG, Sivamani RK, Konia TH, Eisen DB. Squamous cell carcinoma in the setting of chronic hidradenitis suppurativa; report of a patient and update of the literature. Dermatol Online J. 2015;21:13030/qt9q9707dp.
Li Pomi F, Macca L, Motolese A, et al. Neoplastic Implications in Patients Suffering from Hidradenitis Suppurativa under Systemic Treatments. Biomedicines. 2021;9:1594.
Jourabchi N, Fischer AH, Cimino‐Mathews A, et al. Squamous cell carcinoma complicating a chronic lesion of hidradenitis suppurativa: a case report and review of the literature. Int Wound J. 2017;14:435‐438.
Chapman S, Delgadillo D, Barber C, Khachemoune A. Cutaneous squamous cell carcinoma complicating hidradenitis suppurativa: a review of the prevalence, pathogenesis, and treatment of this dreaded complication. Acta Dermatovenerol Alp Pannonica Adriat. 2018;27:25‐28.
Jung JM, Lee KH, Kim Y‐J, et al. Assessment of Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa. JAMA Dermatol. 2020;156:844‐853.
Jedrzejczak MJ, Ingram JR, Lowes MA, et al. Expert Knowledge, Attitudes, and Practices in Management of Hidradenitis Suppurativa Pain. JAMA Dermatol. 2021;157:464‐466.
Helvacı Ö, Güz G, Adışen E, et al. Hidradenitis Suppurativa: a lesser‐known cause of AA amyloidosis. Hippokratia. 2020;24:33‐37.
Kridin K, Amber KT, Comaneshter D, Cohen AD. Amyloidosis in hidradenitis suppurativa: a cross‐sectional study and review of the literature. Clin Exp Dermatol. 2020;45:565‐571.
Utrera‐Busquets M, Romero‐Maté A, Castaño Á, et al. Severe hidradenitis suppurativa complicated by renal AA amyloidosis. Clin Exp Dermatol. 2016;41:287‐289.
Ooi XT, Choi E, Han H, et al. The psychosocial burden of hidradenitis suppurativa in Singapore. JAAD Int. 2023;10:89‐94.
Fauconier M, Reguiai Z, Barbe C, et al. Association between hidradenitis suppurativa and spondyloarthritis. Joint Bone Spine. 2018;85:593‐597.
Rondags A, Arends S, Wink FR, et al. High prevalence of hidradenitis suppurativa symptoms in axial spondyloarthritis patients: A possible new extra‐articular manifestation. Semin Arthritis Rheum. 2019;48:611‐617.
Almuhanna N, Finstad A, Alhusayen R. Association between hidradenitis suppurativa and inflammatory arthritis: A systematic review and meta‐analysis. Dermatology. 2021;237:740‐747.
Gomollón F, Dignass A, Annese V, et al. 3rd European evidence‐based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and Medical management. J Crohns Colitis. 2017;11:3‐25.
Chen W‐T, Chi C‐C. Association of hidradenitis suppurativa with inflammatory bowel disease: A systematic review and meta‐analysis. JAMA Dermatol. 2019;155:1022‐1027.
Tzellos T, Zouboulis CC. Which hidradenitis suppurativa comorbidities should I take into account? Exp Dermatol. 2022;31(Suppl 1):29‐32.
Tzellos T, Zouboulis CC, Gulliver W, et al. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta‐analysis of observational studies. Br J Dermatol. 2015;173:1142‐1155.
Thomi R, Yerly D, Yawalkar N, et al. Interleukin‐32 is highly expressed in lesions of hidradenitis suppurativa. Br J Dermatol. 2017;177:1358‐1366.
Horissian M, Maczuga S, Kirby JS, Nelson AM. Increased risk of alopecia areata for people with hidradenitis suppurativa in a cross‐sectional study. J Am Acad Dermatol. 2019;81:1431‐1432.
Reddy S, Orenstein LAV, Strunk A, Garg A. Incidence of long‐term opioid use among opioid‐naive patients with hidradenitis suppurativa in the United States. JAMA Dermatol. 2019;155:1284‐1290.
Kjaersgaard Andersen R, Saunte SK, Jemec GBE, Saunte DM. Psoriasis as a comorbidity of hidradenitis suppurativa. Int J Dermatol. 2020;59:216‐220.
Lee JH, Kwon HS, Jung HM, et al. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population‐based study. J Eur Acad Dermatol Venereol. 2018;32:1784‐1790.
Broderick L, Hoffman HM. IL‐1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nat Rev Rheumatol. 2022;18:448‐463.
Garcovich S, Genovese G, Moltrasio C, et al. PASH, PAPASH, PsAPASH, and PASS: The autoinflammatory syndromes of hidradenitis suppurativa. Clin Dermatol. 2021;39:240‐247.
Nikolakis G, Kaleta KP, Vaiopoulos AG, et al. Phenotypes and pathophysiology of syndromic hidradenitis suppurativa: different faces of the same disease? A systematic review. Dermatology. 2021;237:673‐697.
Leuenberger M, Berner J, Di Lucca J, et al. PASS syndrome: An IL‐1‐driven autoinflammatory disease. Dermatology. 2016;232:254‐258.
Schneider‐Burrus S, Kalus S, Fritz B, et al. The impact of hidradenitis suppurativa on professional life. Br J Dermatol. 2023;188:122‐130.
Hamzavi IH, Sundaram M, Nicholson C, et al. Uncovering burden disparity: A comparative analysis of the impact of moderate‐to‐severe psoriasis and hidradenitis suppurativa. J Am Acad Dermatol. 2017;77:1038‐1046.
Vinding GR, Miller IM, Zarchi K, et al. The prevalence of inverse recurrent suppuration: a population‐based study of possible hidradenitis suppurativa. Br J Dermatol. 2014;170:884‐889.
Jemec GB. The symptomatology of hidradenitis suppurativa in women. Br J Dermatol. 1988;119:345‐350.
Garg A, Papagermanos V, Midura M, Strunk A. Incidence of hidradenitis suppurativa among tobacco smokers: a population‐based retrospective analysis in the U.S.A. Br J Dermatol. 2018;178:709‐714.
Kromann CB, Ibler KS, Kristiansen VB, Jemec GBE. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014;94:553‐557.
Seyed Jafari SM, Knüsel E, Cazzaniga S, Hunger RE. A retrospective cohort study on patients with hidradenitis suppurativa. Dermatology. 2018;234:71‐78.
Lyons AB, Zubair R, Kohli I, Hamzavi IH. Preoperative ultrasound for evaluation of hidradenitis suppurativa. Dermatol Surg. 2019;45:294‐296.
Martorell A, Giovanardi G, Gomez‐Palencia P, Sanz‐Motilva V. Defining fistular patterns in hidradenitis suppurativa: Impact on the management. Dermatol Surg. 2019;45:1237‐1244.
Griffin N, Williams AB, Anderson S, et al. Hidradenitis suppurativa: MRI features in anogenital disease. Dis Colon Rectum. 2014;57:762‐771.
Zouboulis CC, Nogueira da Costa A, Jemec GBE, Trebing D. Long‐wave medical infrared thermography: A clinical biomarker of inflammation in hidradenitis suppurativa/acne inversa. Dermatology. 2019;235:144‐149.
Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173:1546‐1549.
Saunte DML, Jemec GBE. Hidradenitis suppurativa: Advances in diagnosis and treatment. JAMA. 2017;318:2019‐2032.
Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus. Surgical approach. In: Roenigk RK, Roenigk HH Jr, eds. Dermatologic Surgery – Principles and Practice. 2nd edn. New York: Marcel Dekker, Inc.; 1996:623‐645.
Sartorius K, Emtestam L, Jemec GBE, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161:831‐839.
Chiricozzi A, Faleri S, Franceschini C, et al. AISI: A new disease severity assessment tool for hidradenitis suppurativa. Wounds. 2015;27:258‐264.
Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double‐blind, placebo‐controlled crossover trial. J Am Acad Dermatol. 2010;62:205‐217.
Hessam S, Scholl L, Sand M, et al. A novel severity assessment scoring system for hidradenitis suppurativa. JAMA Dermatol. 2018;154:330‐335.
Goldfarb N, Lowes MA, Butt M, et al. Hidradenitis Suppurativa Area And Severity Index Revised (HASI‐R): Psychometric property assessment. Br J Dermatol. 2021;184:905‐912.
Garg A, Zema C, Kim K, et al. Development and initial validation of the HS‐IGA: A novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials. Br J Dermatol. 2022;187:203‐210.
Marzano AV, Chiricozzi A, Giovanardi G, et al. Creation of a severity index for hidradenitis suppurativa that includes a validated quality‐of‐life measure: The HIDRAscore. J Eur Acad Dermatol Venereol. 2020;34:1815‐1821.
Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): A novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30:989‐994.
Rondags A, van Straalen KR, van Hasselt JR, et al. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient‐reported quality of life and objective disease severity assessment. Br J Dermatol. 2019;180:1214‐1220.
Sartorius K, Lapins J, Emtestam L, Jemec GBE. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149:211‐213.
Zouboulis CC, Gulliver W, Ingram J, et al. Endpoints of clinical trials for Hidradenitis Suppurativa: Proceedings of a round‐table session. Exp Dermatol. 2020;29(Suppl 1):67‐72.
Zouboulis CC, Matusiak Ł, Jemec GBE, et al. Inter‐rater and intrarater agreement and reliability in clinical staging of hidradenitis suppurativa/acne inversa. Br J Dermatol. 2019;181:852‐854.
Kimball AB, Sundaram M, Banderas B, et al. Development and initial psychometric evaluation of patient‐reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa. J Dermatolog Treat. 2018;29:152‐164.
Miller I, Lynggaard CD, Lophaven S, et al. A double‐blind placebo‐controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165:391‐398.
Zouboulis CC. Pain Index: a new prospective hidradenitis suppurativa patient‐reported outcome measure instrument. Br J Dermatol. 2021;184:1203‐1204.
Zouboulis CC, Chernyshov PV. Hidradenitis suppurativa‐specific, patient‐reported outcome measures. J Eur Acad Dermatol Venereol. 2021;35:1420‐1421.
Chiricozzi A, Bettoli V, De Pità O, et al. HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019;33:e24‐26.
Peris K, Lo Schiavo A, Fabbrocini G, et al. HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019;33:766‐773.
Ingram JR, Hadjieconomou S, Piguet V. Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process. Br J Dermatol. 2016;175:263‐272.
Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375:422‐434.
Zouboulis CC. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa. Expert Rev Clin Immunol. 2016;12:1015‐1026.
Zouboulis CC, von Stebut E. Hidradenitis suppurativa/Acne inversa: Von „orphan disease“ zu heilbarer entzündlicher Hauterkrankung. Hautarzt. 2021;72:647‐650.
van der Zee HH, Prens EP, Boer J. Deroofing: A tissue‐saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol. 2010;63:475‐480.
Mikkelsen PR, Dufour DN, Zarchi K, Jemec GBE. Recurrence rate and patient satisfaction of CO2 laser evaporation of lesions in patients with hidradenitis suppurativa: a retrospective study. Dermatol Surg. 2015;41:255‐260.
Hazen PG, Hazen BP. Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg. 2010;36:208‐213.
Cuenca‐Barrales C, Montero‐Vílchez T, Sanchez‐Diaz M, et al. Patterns of Surgical Recurrence in Patients with Hidradenitis Suppurativa. Dermatology. 2023;239:255‐261.
Ovadja ZN, Zugaj M, Jacobs W, et al. Recurrence rates following reconstruction strategies after wide excision of hidradenitis suppurativa: A systematic review and meta‐analysis. Dermatol Surg. 2021;47:e106‐110.
Riddle A, Westerkam L, Feltner C, Sayed C. Current surgical management of hidradenitis suppurativa: A systematic review and meta‐analysis. Dermatol Surg. 2021;47:349‐354.
Ritz JP, Runkel N, Haier J, Buhr HJ. Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis. 1998;13:164‐168.
Altmann S, Fansa H, Schneider W. Axillary hidradenitis suppurativa: A further option for surgical treatment. J Cutan Med Surg. 2004;8:6‐10.
Ellis LZ. Hidradenitis suppurativa: Surgical and other management techniques. Dermatol Surg. 2012;38:517‐536.
Calibre C, Bouhanna A, Salmin J‐P, et al. Hidrosadénite axillaire: une stratégie thérapeutique en un temps. Ann Chir Plast Esthet. 2013;58:670‐675.
Chen E, Friedman HI. Management of regional hidradenitis suppurativa with vacuum‐assisted closure and split thickness skin grafts. Ann Plast Surg. 2011;67:397‐401.
Pearce FB, Richardson KA. Negative pressure wound therapy, staged excision and definitive closure with split‐thickness skin graft for axillary hidradenitis suppurativa: a retrospective study. J Wound Care. 2017;26:S36‐42.
Ge S, Orbay H, Silverman RP, Rasko YM. Negative pressure wound therapy with instillation and dwell time in the surgical management of severe hidradenitis suppurativa. Cureus. 2018;10:e3319.
Tchero H, Herlin C, Bekara F, et al. Two‐stage surgical repair in 31 patients with stage II‐III hidradenitis suppurativa. Int J Dermatol. 2018;57:745‐747.
Mehdizadeh A, Hazen PG, Bechara FG, et al. Recurrence of hidradenitis suppurativa after surgical management: A systematic review and meta‐analysis. J Am Acad Dermatol. 2015;73 (5 Suppl 1):S70‐77.
Paasch U, Zidane M, Baron JM, et al. S2k‐Leitlinie: Lasertherapie der Haut. J Dtsch Dermatol Ges. 2022;20:1248‐1270.
Frew JW, Hawkes JE, Krueger JG. Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms. Ther Adv Chronic Dis. 2019;10:2040622319830646.
Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2009;23:985‐998.
Nikolakis G, von Stebut E. Lokale und neue apparative Therapien der milden Hidradenitis suppurativa. Hautarzt. 2021;72:676‐685.
Jemec GBE. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366:158‐164.
Bettoli V, Zauli S, Borghi A, et al. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa‐acne inversa: a prospective study on 23 patients. J Eur Acad Dermatol Venereol. 2014;28:125‐126.
Dessinioti C, Zisimou C, Tzanetakou V, et al. Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1‐year follow‐up. Clin Exp Dermatol. 2016;41:852‐857.
Yao Y, Jørgensen A‐HR, Ring HC, Thomsen SF. Effectiveness of clindamycin and rifampicin combination therapy in hidradenitis suppurativa: a 6‐month prospective study. Br J Dermatol. 2021;184:552‐553.
Nikolakis G, Kristandt A, Hauptmann M, et al. Efficacy of short‐term intravenous clindamycin prior to oral clindamycin‐rifampicin treatment in hidradenitis suppurativa: a retrospective case series. Br J Dermatol. 2021;185:1270‐1272.
Zouboulis CC, Rabe T. Hormonelle Antiandrogene in der Aknetherapie. J Dtsch Dermatol Ges. 2010;8(Suppl 1):S60‐74.
Sawers RS, Randall VA, Ebling FJ. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol. 1986;115:269‐274.
Matusiak L, Bieniek A, Szepietowski JC. Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients. Br J Dermatol. 2014;171:170‐174.
Gollnick HP, Dümmler U. Retinoids. Clin Dermatol. 1997;15:799‐810.
Verdolini R, Simonacci F, Menon S, et al. Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in women of child‐bearing age. G Ital Dermatol Venereol. 2015;150:155‐162.
Nikolakis G, Kyrgidis A, Zouboulis CC. Is there a role for antiandrogen therapy for hidradenitis suppurativa? A systematic review of published data. Am J Clin Dermatol. 2019;20:503‐513.
Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: A case series of five patients. J Dermatolog Treat. 2006;17:211‐213.
Brocard A, Knol A‐C, Khammari A, Dréno B. Hidradenitis suppurativa and zinc: A new therapeutic approach. A pilot study. Dermatology. 2007;214:325‐327.
Wong D, Walsh S, Alhusayen R. Low‐dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa. J Am Acad Dermatol. 2016;75:1059‐1062.
Anderson MD, Zauli S, Bettoli V, et al. Cyclosporine treatment of severe Hidradenitis suppurativa–A case series. J Dermatolog Treat. 2016;27:247‐250.
Vossen ARJV, van Doorn MBA, van der Zee HH, Prens EP. Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. J Am Acad Dermatol. 2019;80:80‐88.
Zouboulis CC, Okun MM, Prens EP, et al. Long‐term adalimumab efficacy in patients with moderate‐to‐severe hidradenitis suppurativa/acne inversa: 3‐year results of a phase 3 open‐label extension study. J Am Acad Dermatol. 2019;80:60‐69.e2.
Zouboulis CC, Hansen H, Caposiena Caro RD, et al. Adalimumab dose intensification in recalcitrant hidradenitis suppurativa/acne inversa. Dermatology. 2020;236:25‐30.
Sánchez Martínez EM, Murray G, Alfageme Roldán F, et al. Adalimumab dose intensification in hidradenitis suppurativa: effectiveness and safety results of a multicentre study. Br J Dermatol. 2021;185:863‐865.
Tzellos T, Yang H, Mu F, et al. Impact of hidradenitis suppurativa on work loss, indirect costs and income. Br J Dermatol. 2019;181:147‐154.
Shih T, Lee K, Grogan T, et al. Infliximab in hidradenitis suppurativa: A systematic review and meta‐analysis. Dermatol Ther. 2022;35:e15691.
Lesage C, Adnot‐Desanlis L, Perceau G, et al. Efficacy and tolerance of prolonged infliximab treatment of moderate‐to‐severe forms of hidradenitis suppurativa. Eur J Dermatol. 2012;22:640‐644.
Ghias MH, Johnston AD, Kutner AJ, et al. High‐dose, high‐frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa. J Am Acad Dermatol. 2020;82:1094‐1101.
Grau‐Pérez M, Rodríguez‐Aguilar L, Roustan G, Alfageme F. Drug survival of adalimumab biosimilar vs adalimumab originator in hidradenitis suppurativa: Can equivalence be assumed? A retrospective cohort study. J Eur Acad Dermatol Venereol. 2023;37:e678‐680.
Kirsten N, Ohm F, Gehrdau K, et al. Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response‐data from the German HS registry HSBest. Life (Basel). 2022;12:1518.
Burlando M, Fabbrocini G, Marasca C, et al. Adalimumab originator vs. biosimilar in hidradenitis suppurativa: A multicentric retrospective study. Biomedicines. 2022;10:2522.
Roccuzzo G, Rozzo G, Burzi L, et al. Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness? Dermatol Ther. 2022;35:e15803.
Montero‐Vilchez T, Cuenca‐Barrales C, Rodriguez‐Tejero A, et al. Switching from adalimumab originator to biosimilar: Clinical experience in patients with hidradenitis suppurativa. J Clin Med. 2022;11:1007.
Moran B, Sweeney CM, Hughes R, et al. Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, Which is corrected by anti‐tnf therapy. J Invest Dermatol. 2017;137:2389‐2395.
Schlapbach C, Hänni T, Yawalkar N, Hunger RE. Expression of the IL‐23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65:790‐798.
Kelly G, Hughes R, McGarry T, et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol. 2015;173:1431‐1439.
Glatt S, Jemec GBE, Forman S, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: A phase 2, double‐blind, placebo‐controlled randomized clinical trial. JAMA Dermatol. 2021;157:1279‐1288.
Frew JW, Navrazhina K, Grand D, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open‐label cohort study. J Am Acad Dermatol. 2020;83:1341‐1348.
Frew JW, Navrazhina K, Sullivan‐Whalen M, et al. Weekly administration of brodalumab in hidradenitis suppurativa: an open‐label cohort study. Br J Dermatol. 2021;184:350‐352.
Esme P, Botsali A, Akoglu G, Caliskan E. An anti‐interleukin‐17a monoclonal antibody, ixekizumab, in the treatment of resistant hidradenitis suppurativa: A case series. Skin Appendage Disord. 2022;8:342‐345.
Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: A randomized clinical trial. JAMA Dermatol. 2016;152:52‐59.
Blok JL, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174:839‐846.
Montero‐Vilchez T, Pozo‐Román T, Sánchez‐Velicia L, et al. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review. J Dermatolog Treat. 2022;33:348‐353.
Kozera E, Flora A, Frew JW. Real‐world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study. J Am Acad Dermatol. 2022;87:1440‐1442.
Ravi M, Trinidad J. Botulinum toxin in hidradenitis suppurativa: A systematic review. J Drugs Dermatol. 2022;21:408‐412.
Geoghegan L, Rodrigues R, Harrison CJ, Rodrigues JN. The use of botulinum toxin in the management of hidradenitis suppurativa: A systematic review. Plast Reconstr Surg Glob Open. 2022;10:e4660.
Grimstad Ø, Tzellos T, Dufour DN, et al. Evaluation of medical and surgical treatments for hidradenitis suppurativa using real‐life data from the Scandinavian registry (HISREG). J Eur Acad Dermatol Venereol. 2019;33:1164‐1171.
Chernyshov PV, Zouboulis CC, Tomas‐Aragones L, et al. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on quality of life and patient‐oriented outcomes and acne, rosacea and hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019;33:1633‐1643.
Chernyshov PV, Finlay AY, Tomas‐Aragones L, et al. Quality of life in hidradenitis suppurativa: An update. Int J Environ Res Public Health. 2021;18:6131.